Disclosed are biaryl azabicyclic derivatives represented by general formula (I). An example of a compound represented by general formula (I) is 2-[(endo )-8-Methyl-8-azabicyclo[3 .2.1]octan-3-yloxy ]-5-(1H-indol-5-yl)-thiazole. The compounds of formula (I) are used to treat alpha-7 and alpha-4-beta-2 nicotinic acetylcholine receptor-mediated conditions or disorders such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimers disease, mild cognitive impairment, senile dementia, AIDS dementia, Picks Disease, dementia associated with Lewy bodies, dementia associated with Downs syndrome, amyotrophic lateral sclerosis, Huntingtons disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammation, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, rheumatoid arthritis, Crohns disease, ulcerative colitis, inflammatory bowel disease, organ transplant rejection, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, septic shock, toxic shock syndrome, sepsis syndrome, depression, rheumatoid spondylitis, and substance abuse.
